Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Jubilant Draximage Inc., dba Jubilant Radiopharma

US Class II Ongoing · initiated 2024-11-22

Failed Stability Specifications

Benzo-Jel (Cherry)

Canada Unclassified Ongoing · initiated 2024-11-22

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2024-11-19

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2024-11-19

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2024-11-19

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

Mylan Institutional, Inc.

US Class II Ongoing · initiated 2024-11-19

Subpotent and Superpotent Drug

PREGABALIN

Canada Type II Ongoing · initiated 2024-11-19

Product quality - Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or …

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Viatris Inc

US Class II Ongoing · initiated 2024-11-18

Superpotent Drug and Subpotent Drug: potency failures obtained

Endo USA, Inc.

US Class I Ongoing · initiated 2024-11-18

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Endo USA, Inc.

US Class I Ongoing · initiated 2024-11-18

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.